|
Bioxel benefits from a significant paclitaxel production capacity through a development and manufacturing agreement with Ampac Fine Chemicals in Rancho Cordova, California. This partnership has brought Bioxel's annual paclitaxel production capacity to 120 kilograms. The FDA-inspected site is recognized worldwide for potent and cytotoxic handling of active pharmaceutical ingredients (APIs) and registered pharmaceutical intermediates. Our process has been fully validated in compliance with international (FDA and Q-7A) regulatory requirements for pharmaceutical APIs, allowing our customers to use Bioxel's paclitaxel in commercial formulation products in North America and Europe.
To find out more about Ampac Fine Chemicals: www.ampacfinechemicals.com
|
Bioxel's business operations are focused on a broad range of ethical and generic pharmaceutical companies in North America and Europe.
In December 2005 and February 2006, Bioxel successively entered into paclitaxel manufacturing and supply agreements with two leading European generic manufacturers. These agreements mark the Corporation's initial breakthrough in Europe. In January 2005, Bioxel also signed a sales agency relationship with the French company Unipex for commercial representation in France. Unipex is a subsidiary of the Canadian company Atrium Biotechnologies Inc., a member of the Canadian Life Sciences Group AeternaZentaris.
To find out more about Unipex:
www.unipex.com |
In January 2005, Bioxel initiated a development agreement in partnership with the Université de Montréal and the University of Toronto to formulate anticancer drugs whit improved efficacy and lower side effects than existing chemotherapy treatments. The project is currently at the pre-clinical exploratory stage and is partially funded by a contribution of $300,000 from the Natural Sciences and Engineering Research Council of Canada (NSERC).
In February 2002, Bioxel signed an agreement with the Israeli company Polygene of Jerusalem to develop injectable paclitaxel-based implants for the localized treatment of inoperable tumors. Currently at the regulatory preclinical stage, the project is partially funded by the Canada-Israel Industrial Research and Development Foundation (CIIRDF).
|
|
